Moleculin Biotech, Inc. Business Operations Contracts & Agreements
13 Contracts & Agreements
- Advisory Agreements (1 contract)
- Agency Agreements (4)
- Development Agreements (4)
- Indemnification Agreements (1)
- Sales Agreements (3)
- Form of Placement Agency Agreement (Filed With SEC on December 21, 2023)
- Portfolio Development Advisor Agreement dated September 6, 2022 between KEWAT, LLC and Moleculin Biotech, Inc (Filed With SEC on November 10, 2022)
- Form of Indemnification Agreement between Moleculin Biotech, Inc. and its officers and directors (Filed With SEC on August 11, 2021)
- At Market Issuance Sales Agreement, dated July 17, 2020, by and among the Company and Oppenheimer & Co. Inc (Filed With SEC on July 17, 2020)
- Scientific Advisory Board Agreement, dated (Filed With SEC on March 19, 2020)
- Placement Agency Agreement, dated February 6, 2020, by and between the Company and Oppenheimer & Co. Inc (Filed With SEC on February 6, 2020)
- At Market Issuance Sales Agreement, dated July 23, 2019, by and among the Company and Oppenheimer & Co. Inc (Filed With SEC on July 24, 2019)
- Placement Agency Agreement, dated as of June 20, 2018 by and between Moleculin Biotech, Inc. and Roth Capital Partners, LLC (Filed With SEC on June 21, 2018)
- Placement Agency Agreement, dated as of February 16, 2018 by and between Moleculin Biotech, Inc. and Roth Capital Partners, LLC (Filed With SEC on February 16, 2018)
- At Market Issuance Sales Agreement, dated September 15, 2017, by and among the Company, Roth Capital Partners, LLC and National Securities Corporation (Filed With SEC on September 15, 2017)
- PATENT AND TECHNOLOGY DEVELOPMENT ANDLICENSE AGREEMENT (Filed With SEC on April 15, 2016)
- PATENT AND TECHNOLOGY DEVELOPMENT AND LICENSEAGREEMENT (Filed With SEC on March 22, 2016)
- PATENT AND TECHNOLOGY DEVELOPMENT ANDLICENSE AGREEMENT (Filed With SEC on March 22, 2016)
